Humacyte uses smooth muscle cells isolated from cadavers to create a collagen matrix. The cells are grown on a biodegradable scaffold for 8-10 weeks. The original scaffold degrades, leaving just the cells and the collagen matrix. In a final step, researchers remove the cells and leave only the matrix. Without the cells, the non-immunogenic matrix can be used as a 'universal' off-the-shelf medical device. It can be grown in tube, sheet, or particulate form. Once implanted, host cells infiltrate, which then integrate and remodel the graft as if it were a natural body part.
21 Davis Drive
Suite 140
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
